Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBRA
NCT04852887Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Jun 2021
- Primary completion
- Apr 2031
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by NRG Oncology. Primary endpoint: Time to invasive or noninvasive ipsilateral breast tumor recurrence at 5 years. Started Jun 2021; status: recruiting.
Beyond the preview
Go deeper on NCT04852887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04852887.